

In the Claims

Claims 28-31 and 74 have been amended as follows:

- a2
28. The isolated polypeptide of 25, which is antigenic.
29. The isolated polypeptide of claim 25, which promotes angiogenesis.
30. The isolated polypeptide of claim 25, which promotes epithelialization.
31. The isolated polypeptide of claim 25, which promotes vascularization.
- a3
74. An isolated polynucleotide encoding the polypeptide of claim 1.

Remarks

The specification has been amended to claim benefit of priority.

The claims have been amended to correct multiple claim dependencies and reduce the claim calculation fees.

No new matter has been added by way of this amendment.

09935726-082401
104280-92/52660